The Technical Analyst
Mesoblast Limited [MESO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Mesoblast Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.00% $5.11
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 554.67 mill |
| EPS: | -0.870 |
| P/E: | -5.87 |
| Earnings Date: | Aug 28, 2024 |
| SharesOutstanding: | 108.55 mill |
| Avg Daily Volume: | 2.27 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | n/a | |||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.87 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.00x |
| Company: PE -5.87 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.437 (-128.12%) $-6.55 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.66 - 5.56 ( +/- 8.77%) |
| ATR Model: 14 days |
Forecast:
16:00 - $5.11
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.11
Forecast 2: 16:00 - $5.11
Forecast 3: 16:00 - $5.11
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.11 (2.00% ) |
| Volume | 0.268 mill |
| Avg. Vol. | 2.27 mill |
| % of Avg. Vol | 11.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MESO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MESO
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Last 10 Buy Signals
Latest Press Releases
2024-03-25 22:34:00 - Press Release
United States Food & Drug Administration (fda) Notifies Mesoblast That Available Clinical Data From Phase 3 Trial Appear Sufficient To Support Bla Submission For Remestemcel-l In Children With Steroid-refractory Acute Graft Versus Host Disease (sr-agvhd)
New york, march 25, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that u.s. fda has informed the company that following additional consideration the available clinical data from its phase 3 study msb-gvhd001 appears sufficient to support submission of the proposed biologics license application (bla) for remestemcel-l for treatment of pediatric patients with steroid-refractory acute graft versus host disease (sr-agvhd).
2024-03-13 19:30:00 - Press Release
Mesoblast Successfully Completes Placement And Accelerated Entitlement Offer
New york, march 13, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 december, 2023 (entitlement offer). together the entitlement offer and institutional placement raised gross proceeds of a$97 million, including a$36.7 million committed today on the same terms as the entitlement offer, primarily from mesoblast's existing major shareholders.
2024-03-10 19:54:00 - Press Release
United States Food & Drug Administration (fda) Supports Accelerated Approval Pathway For Rexlemestrocel-l In End-stage Heart Failure Patients With A Left Ventricular Assist Device (lvad)
New york, march 10, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that u.s. fda supports an accelerated approval pathway for rexlemestrocel-l, mesoblast's allogeneic mesenchymal precursor cell (mpc) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (hfref) and a left ventricular assist device (lvad). fda provided this feedback in formal minutes to the company following the type b meeting held with fda on february 21, 2024 for rexlemestrocel-l (revascor®) under the existing regenerative medicine advanced therapy (rmat) designation.
2024-02-28 17:57:00 - Press Release
Mesoblast Reports Financial Results And Operational Update For Half-year Ended December 31, 2023
New york, feb. 28, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended december 31, 2023.
2024-02-26 07:00:00 - Press Release
Mesoblast Financial Results And Corporate Update Webcast
New york, feb. 26, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the six months ended december 31, 2023.
Latest News
2024-04-03 07:00:00 - InvestorPlace
Feeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025
For bold investors, there are few opportunities as exciting as chasing 10x returns in the stock market. Make no mistake about it, the stock market offers up multiple opportunities to turn $1 into $10 quickly.
2024-03-27 12:01:05 - Zacks Investment Research
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
2024-02-26 07:00:00 - GlobeNewsWire
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the six months ended December 31, 2023.
2024-01-26 07:03:19 - Benzinga
Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2024-01-19 12:31:07 - Zacks Investment Research
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
2024-01-05 11:18:56 - Zacks Investment Research
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Mesoblast Limited (MESO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-12-22 18:37:52 - Seeking Alpha
Mesoblast Has Major Hurdles
The FDA has rejected Mesoblast's cell therapy candidate for pediatric acute graft versus host disease, causing the stock to decline. Mesoblast is an old company located in Australia, which may impact its resonance with the FDA. The FDA has a bias against cell and other human biologic therapies, making approval for Mesoblast's therapy challenging.
2023-12-21 11:17:53 - Zacks Investment Research
5 Stocks to Ride the Santa Claus Rally
Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in the seven-day period.
2023-08-30 22:25:26 - Seeking Alpha
Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO ) Q4 2023 Results Conference Call August 30, 2023 6:30 PM ET Company Participants Dr. Silviu Itescu - Chief Executive Officer Dr. Eric Rose - Chief Medical Officer Andrew Chaponnel - Interim Chief Financial Officer Dr. Philip Krause - Board Member Conference Call Participants Louise Chen - Cantor Edward Tenthoff - Piper Sandler Sami Corwin - William Blair John Hester - Bell Potter Operator Hello and welcome to the Mesoblast Financial Results for the Period Ended June 30, 2023. An announcement and presentation have been lodged with the ASX and are also available on the home and investor pages@www.mesoblast.com.
2023-08-07 12:01:16 - The Motley Fool
Why Shares of Mesoblast Are Down Monday
Several analysts have recently downgraded their positions on the pharmaceutical stock. Mesoblast focuses on therapies derived from the cells of the bone marrow from healthy donors.